GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (TSX:IN) » Definitions » Gross Margin %

InMed Pharmaceuticals (TSX:IN) Gross Margin % : 26.14% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is InMed Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. InMed Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was C$0.44 Mil. InMed Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was C$1.66 Mil. Therefore, InMed Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 26.14%.


The historical rank and industry rank for InMed Pharmaceuticals's Gross Margin % or its related term are showing as below:

TSX:IN' s Gross Margin % Range Over the Past 10 Years
Min: 33.92   Med: 41.94   Max: 49.95
Current: 38.42


During the past 13 years, the highest Gross Margin % of InMed Pharmaceuticals was 49.95%. The lowest was 33.92%. And the median was 41.94%.

TSX:IN's Gross Margin % is ranked worse than
71.68% of 738 companies
in the Biotechnology industry
Industry Median: 59.44 vs TSX:IN: 38.42

InMed Pharmaceuticals had a gross margin of 26.14% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for InMed Pharmaceuticals was 0.00% per year.


InMed Pharmaceuticals Gross Margin % Historical Data

The historical data trend for InMed Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Gross Margin % Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 50.00 33.92

InMed Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.90 18.66 67.95 2.30 26.14

Competitive Comparison of InMed Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, InMed Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Gross Margin % falls into.



InMed Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

InMed Pharmaceuticals's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=1.9 / 5.495
=(Revenue - Cost of Goods Sold) / Revenue
=(5.495 - 3.631) / 5.495
=33.92 %

InMed Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.4 / 1.664
=(Revenue - Cost of Goods Sold) / Revenue
=(1.664 - 1.229) / 1.664
=26.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


InMed Pharmaceuticals  (TSX:IN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

InMed Pharmaceuticals had a gross margin of 26.14% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


InMed Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (TSX:IN) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (TSX:IN) Headlines

No Headlines